Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Table 2 Average duration of untreated attacks

	Underweight BMI	Normal BMI	Overweight BMI	Obese BMI
Baseline
Average duration of attack (h)
n	12	150	106	41
Mean ± SD^a	50.7 ± 22.9	40.5 ± 32.4	45.9 ± 31.5	44.4 ± 35.5
Median (range)	48.0 (6–92)	41.0 (0–140)	48.0 (0–156)	48.0 (0–120)
Follow-up
Average duration of attack (h)
n	11	76	70	25
Mean ± SD^a	34.6 ± 21.6	39.7 ± 31.1	37.6 ± 30.6	44.2 ± 29.9
Median (range)	36 (0–72)	37.5 (0–144)	28.7 (0–120)	48.0 (0.3–120)

Average duration of untreated attacks corresponds to mean of average durations of untreated attacks at the skin, abdomen, larynx, and other sites
BMI body mass index; SD standard deviation; n = the number of patients
^aP values comparing average duration of attack at baseline between patients with normal/overweight/obese BMI: P = 0.408 at baseline; P = 0.530 at follow-up. Results excluding data from the two reinjection outliers are presented in Additional file 1: Table S2

ISSN: 2045-7022